Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination

Abstract Background The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponde...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases Jg. 227; H. 5; S. 651 - 662
Hauptverfasser: Jongkees, Marlou J, Geers, Daryl, Hensley, Kathryn S, Huisman, Wesley, GeurtsvanKessel, Corine H, Bogers, Susanne, Gommers, Lennert, Papageorgiou, Grigorios, Jochems, Simon P, den Hollander, Jan G, Schippers, Emile F, Ammerlaan, Heidi S M, Bierman, Wouter F W, van der Valk, Marc, Berrevoets, Marvin A H, Soetekouw, Robert, Langebeek, Nienke, Bruns, Anke H W, Leyten, Eliane M S, Sigaloff, Kim C E, van Vonderen, Marit G A, Delsing, Corine E, Branger, Judith, Katsikis, Peter D, Mueller, Yvonne M, de Vries, Rory D, Rijnders, Bart J A, Brinkman, Kees, Rokx, Casper, Roukens, Anna H E
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Oxford University Press 01.03.2023
Schlagworte:
2019-nCoV Vaccine mRNA-1273
Ad26COVS1
Aged
Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
ChAdOx1 nCoV-19
COVID-19
COVID-19 Vaccines
Female
HIV Infections
Humans
Male
Middle Aged
Prospective Studies
SARS-CoV-2
Vaccination
COVID-19
HIV
nonresponder
SARS-CoV-2 vaccines
additional dose
ISSN:0022-1899, 1537-6613, 1537-6613
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders. Methods The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. Results Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60–66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423–941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24–46) to 4317 BAU/mL (95% CI, 3275–5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed. Conclusions An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N. An additional 100 µg mRNA-1273 vaccination substantially increased SARS-CoV-2 S1-specific binding antibody levels in people with HIV with a serological hyporesponse after a primary vaccination regimen. This response was observed regardless of the primary vaccination regimen or patient characteristics.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
1537-6613
DOI:10.1093/infdis/jiac451